Evotec SE
EVOHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeEvotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. At a $533.1M market cap, Evotec SE ranks as a small-cap company within healthcare. It operates in two segments, Shared R&D and Just Evotec Biologics.
Market Cap
$533.1M
Beta
1.27
P/E (TTM)
—
P/E (Fwd)
-7.89
EPS (TTM)
$-0.63
EPS (Fwd)
$-0.19
ROE
-26.1%
ROA
-5.4%
Cash
$465.6M
Total Debt
$475.9M
Free CF
-$81.0M
52W Change
-63.4%
Annual Financials
Cash vs Debt
Where EVO stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, EVO finished 39.66% below its 150-day moving average ($2.37) and 45.83% below its 200-day moving average ($2.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EVO overbought or oversold?
At the October 15, 2026 close, EVO's RSI(14) was 43.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Evotec SE carries $475.9M in total debt against $465.6M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$81.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -26.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $751.4M (2022) to $788.4M (2025).
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing EVO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.